Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 7/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401966 | 1.00 | SYK (0.58) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL18575403 | 0.91 | SYK (0.56) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL25318929 | 0.91 | SYK (0.56) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL17513638 | 0.91 | SYK (0.56) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL21834805 | 0.90 | SYK (0.55) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL1556449 | 0.89 | SYK (0.60) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL143120 | 0.89 | SYK (0.60) | SYKCASP1CTRB1MAPTCTSK | |
| SCHEMBL12849605 | 0.89 | SYK (0.69) | SYKCTRB1MAPTCTSKATM | |
| SCHEMBL25256638 | 0.89 | SYK (0.62) | SYKCASP1CTRB1CTSKATM | |
| SCHEMBL25301720 | 0.89 | SYK (0.62) | SYKCASP1CTRB1CTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-3953376-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | Protagonist Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113631569-A | Process for the synthesis of beta-homoamino acids | 领导医疗有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2020198682-A1 | METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2017165676-A1 | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PSMA7, ITGB7, SCN7A | SYK 4712/4885CASP1 3905/4885CTRB1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.